EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
14 May 2019

EBE announces the appointment of Michele Antonelli as Vice-President

Brussels, 14 May 2019 – The European Biopharmaceutical Enterprises (EBE) is pleased to announce the appointment of Mr Michele Antonelli, Chief Executive Officer of Stallergenes Greer, as EBE Vice-Pr...

Read more
17 Apr 2019

Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships

Brussels, 17 April 2019 The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon...

Read more
26 Nov 2018

Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships

Brussels, 26 November 2018 - Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships  The six undersigned European health industry associations are ambitious...

Read more
15 Oct 2019

EBE Position Paper: “A Risk-Based Approach to Identity Sampling of Biological Drug Substances”

Good Manufacturing Practices require that the identity of materials received for use in the manufacturing of drug products is confirmed. However, the direct sampling of primary containers of biologica...

Read more
26 Aug 2019

EBE-EFPIA Position Paper: An Industry Perspective on Article 117 of the EU Medical Device Regulation: Labelling Requirements for Prefilled, Non-Reusable, Integral Drug-Delivery Device Combination Products

Prefilled, non-reusable, integral drug-device combinations (DDCs) are regulated as medicinal products, if the intention is to administer the medicinal product to the patient. However, the device compo...

Read more
12 Aug 2019

EBE-EFPIA Position Paper: An Industry Perspective on Article 117 of the EU Medical Device Regulation: Clinical Requirements for Prefilled, Single-Use, Integral Drug-Device Combination Products

Prefilled, single-use, integral drug-device combinations (DDCs) are regulated as medicinal products. However, the device component needs to conform with “relevant” General Safety and Performance R...

Read more
19 Feb 2019

Exit Strategies for SME Life Science Companies in the EU

When funding life science companies, investors need realistic expectations on how to recover their investment and, potentially, returns on their investment. A number of options exist, commonly c...

Read more
20 Jun 2018

Incentives, IP and Smaller Companies: The Story of uniQure

Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands  and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe geneti...

Read more
07 Jun 2018

KPMG Report: Site Selection for Life Sciences Companies in Europe 2018

EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...

Read more

From Twitter

30 million people in Europe live with a #raredisease. #WeWontRest until we make rare diseases even rarer #Care4Rare https://t.co/dLxjn48Aot

The programme for @EBE_EU’s annual #ATMPs conference "Handling the ATMPs challenges to timely meet #patients needs" is now live! https://t.co/UBJl7qGMt8. Register here: https://t.co/kQW5HtnicH
#advancedtherapies #biotech

Read IMI's September newsletter, featuring Pierre Meulien on #AdvancedTherapies + stories from our projects on #Ebola #SLCs #SocialMedia & #Pharmacovigilance + #iPSC
Read it online & sign up for future issues https://t.co/5Erx6XpNGx
#IMICarryTheTorch #EUHealthResearch #H2020

Follow us